---
title: "Zydus 的藥物 Desidustat 用於治療腎性貧血已獲得中國監管機構的批准"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/279125432.md"
description: "Zydus Lifesciences 已獲得中國國家藥品監督管理局對其藥物 Desidustat 的批准，該藥物用於治療慢性腎病（CKD）患者的腎性貧血。該藥物已授權給中國醫療系統控股的子公司 CMS International Development and Management Ltd。Zydus 旨在改善患者的治療效果，並擴大在大中華區的 CKD 治療覆蓋面，該地區有超過 1.2 億 CKD 患者。Desidustat 在印度以 Oxemia 的品牌銷售，自 2022 年上市以來，已有超過 100,000 名患者接受治療"
datetime: "2026-03-14T06:01:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279125432.md)
  - [en](https://longbridge.com/en/news/279125432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279125432.md)
---

# Zydus 的藥物 Desidustat 用於治療腎性貧血已獲得中國監管機構的批准

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia.

The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd.

CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020.

Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure.

"We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement.

The company is happy to partner with CMS and is confident that this will expand access to patients suffering from Chronic Kidney Disease across Greater China, he added.

Desidustat is discovered, developed and marketed by Zydus in India under the brand name Oxemia. More than 1 lakh CKD patients in India have been successfully treated with Oxemia since its launch in 2022, the drug firm stated.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China.

### 相關股票

- [8A8.SG](https://longbridge.com/zh-HK/quote/8A8.SG.md)

## 相關資訊與研究

- [盧寵茂轉抵蘇黎世鼓勵瑞士藥廠善用「1+」藥物審批機制](https://longbridge.com/zh-HK/news/287196275.md)
- [工研院串聯跨法人能量 打造國家藥物韌性防線](https://longbridge.com/zh-HK/news/287186590.md)
- [美國 FDA 測試即時取得臨牀試驗資料，以利加速藥物審核](https://longbridge.com/zh-HK/news/286686699.md)
- [已逾 8 千人服用！血管炎藥在日本造成 20 死 藥商籲暫停給藥](https://longbridge.com/zh-HK/news/286640523.md)
- [全球藥物韌性高峰會登場 經濟部佈局數位製造](https://longbridge.com/zh-HK/news/287002422.md)